Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Menstrual Migraine Treatment With TREXIMET (Formerly Known as TREXIMA)

ClinicalTrials.gov ID: NCT00329355

Public ClinicalTrials.gov record NCT00329355. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 6:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Single Migraine Attack, Placebo-controlled, Parallel-group Multicenter Study to Evaluate the Efficacy and Tolerability of Trexima (Sumatriptan Succinate.Naproxen Sodium) Tablets vs Placebo When Administered During the Mild Pain Phase of Menstrual Migraine in Women With Dysmenorrhea

Study identification

NCT ID
NCT00329355
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
351 participants

Conditions and interventions

Interventions

  • sumatriptan succinate/naproxen sodium Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2006
Primary completion
Oct 31, 2006
Completion
Oct 31, 2006
Last update posted
Jan 22, 2017

2006

United States locations

U.S. sites
35
U.S. states
22
U.S. cities
33
Facility City State ZIP Site status
GSK Investigational Site Chandler Arizona 85224
GSK Investigational Site Irvine California 92618
GSK Investigational Site Redondo Beach California 90277
GSK Investigational Site San Francisco California 94109
GSK Investigational Site Santa Monica California 90404
GSK Investigational Site Boulder Colorado 80304
GSK Investigational Site Colorado Springs Colorado 80909
GSK Investigational Site Port Orange Florida 32127
GSK Investigational Site Sunrise Florida 33351
GSK Investigational Site West Palm Beach Florida 33407
GSK Investigational Site Chicago Illinois 60614
GSK Investigational Site South Bend Indiana 46601
GSK Investigational Site Baton Rouge Louisiana 70808
GSK Investigational Site Ann Arbor Michigan 48104
GSK Investigational Site Omaha Nebraska 68134
GSK Investigational Site Albuquerque New Mexico 87108
GSK Investigational Site New York New York 10021
GSK Investigational Site New York New York 10022
GSK Investigational Site Winston-Salem North Carolina 27103
GSK Investigational Site Cincinnati Ohio 45245
GSK Investigational Site Cincinnati Ohio 45267
GSK Investigational Site Toledo Ohio 43614-5809
GSK Investigational Site West Chester Ohio 45069
GSK Investigational Site Oklahoma City Oklahoma 73104
GSK Investigational Site Portland Oregon 97210
GSK Investigational Site Carnegie Pennsylvania 15106
GSK Investigational Site Philadelphia Pennsylvania 19114
GSK Investigational Site Warwick Rhode Island 02886
GSK Investigational Site Mt. Pleasant South Carolina 29464
GSK Investigational Site Nashville Tennessee 37203
GSK Investigational Site Georgetown Texas 78626
GSK Investigational Site Houston Texas 77054
GSK Investigational Site San Antonio Texas 78229
GSK Investigational Site Salt Lake City Utah 84109
GSK Investigational Site Seattle Washington 98195

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00329355, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 22, 2017 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00329355 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →